Effect of LASER Photobiomodulation Therapy on Chronic Pain and Opioid Weaning

This study will examine the effect of LASER photobiomodulation therapy on pain and opioid pain medication weaning on patients who are undergoing opioid pain medication weaning.

Study Overview

• Status: Terminated
• Conditions: Chronic Pain
• Intervention / Treatment: Device: LightForce EXPi

Detailed Description

The primary objective of this study is to determine if treatment with LASER photobiomodulation therapy reduces pain and facilitates opioid pain medication (OPM) reduction (weaning). The subject group includes patients with chronic pain who are undergoing OPM weaning and are candidates for LASER photobiomodulation therapy. This is a prospective interventional study using a double-blind 4-period crossover design to assess the efficacy of HIGH POWER LASER photobiomodulation therapy compared to sham (LOW POWER LASER) therapy in reducing pain and improving compliance with OPM weaning.

• Study Type: Interventional
• Enrollment (Actual): 12
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • California
    • San Diego, California, United States, 92123
      • Sharp Alison DeRose Rehabilitation Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age 18 or older.
• Taking prescribed opioid pain medications in an amount in excess of 30 Morphine Equivalent Dose (MED) for 6 months or longer.
• Have been recommended to wean or reduce their MED.
• Medically stable such that subject does not have unstable angina, COPD requiring supplemental oxygen, untreated or active cancer or similar conditions that would make participation difficult or unsafe.
• Compliant with all physician recommendations relating to medication usage.
• Ambulatory and able to use the toilet independently.
• Negative pregnancy test in subjects of childbearing potential
• Willing to attempt opioid pain medication taper.
• Competent to provide informed consent.
• Capable of understanding and completing study questionnaires.
• Subject willing to participate in the study for up to 12 weeks.

Exclusion Criteria:

• Not capable of understanding or completing study questionnaires.
• Lacking capacity to provide fully informed consent.
• Substance use disorder not in remission.
• Considering surgery or other invasive procedures that would take place during the study.
• Used isotretinoin (Accutane) within 6 months prior to study enrollment
• Cancer not in remission.
• Need of ongoing Transcutaneous Electrical Nerve Stimulation (TENS) therapy, massage therapy, chiropractic care or other treatments intended to remediate pain other than treatment in the Sharp Pain Program.
• A female who is pregnant or lactating, or of childbearing potential unless a medically acceptable method of birth control is in use.
• Any use of light-activated drugs (photodynamic therapy) or heat sensitive medications within 30 days of first treatment.
• Used an investigational drug/device therapy or participated in any clinical investigation relating to pain within 4 weeks prior to study enrollment.
• A psychiatric or psychological condition that would place undo stress on the subject, prevent full participation or compromise data collection.
• The subject is otherwise determined, based on the opinion of the Investigator, to be an unsuitable candidate for enrollment in this study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: DOUBLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
OTHER: ABAB; Treatment, either LASER (arm A) or LOW LEVEL LASER (arm B) will be provided 3 (not less than 2) days a week for three weeks at which time crossover into the alternate arm occurs (BABA to ABAB or ABAB to BABA). ABAB initial period is active treatment - LASER. Active Treatment: LASER light is delivered to the skin and deeper tissues affected by pain using either a wand or glass roller ball. Ten to 25 Watts of LASER energy is delivered to the painful regions for 8 to 16 minutes depending on the size of the area treated and other factors such as skin pigmentation.	Device: LightForce EXPi; LASER photobiomodulation therapy of 15-25 watts of coherent infrared light to affected area for 10 minutes using wand-type probe.; Other Names: LASER photobiomodulation therapy; LASER therapy
OTHER: BABA; Treatment, either LASER (arm A) or LOW LEVEL LASER (arm B) will be provided 3 (not less than 2) days a week for three weeks at which time crossover into the alternate arm occurs (BABA to ABAB or ABAB to BABA). BABA initial period is sham treatment - LOW LEVEL LASER. LOW LEVEL LASER "treatment": Low level LASER is provided in a similar fashion using LASER power levels (1 Watt) that produce warmth only at superficial skin levels.	Device: LightForce EXPi; LASER photobiomodulation therapy of 15-25 watts of coherent infrared light to affected area for 10 minutes using wand-type probe.; Other Names: LASER photobiomodulation therapy; LASER therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Compliance with Medical Opioid Use Reduction Protocol	Prescriptions for pain medications will be provided each week. Each successive prescription will have a decreasing quantity of tablets consistent with an agreed upon taper rate. Taper rates will be roughly based upon the recommendations of the CDC (10% per week). Subjects will have the option of postponing the taper by one week as often as every other week. If a subject was to exercise every option available to them to delay taper, then the weaning process would take twice as long and the rate of taper would be cut in half. The study will compare the number of missed medication tapers, and the taper rates of patients in the HIGH POWER LASER treatment periods to those in the LOW LEVEL LASER THERAPY treatment periods.	12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Self-reported measure of Pain.	Participants will complete the Visual Analogue Scale for Pain (Wong Baker FACES pain rating scale), taken at baseline, weekly thereafter, and immediately after the last treatment.	12 weeks
Self-reported measure of Quality of Life.	Participants will complete the 36-Item Short Form Health Survey (SF36) at baseline and at study completion.	12 weeks
Self-reported measure of Depression.	Participants will complete the 17-item Hamilton Depression Rating Scale (HAM-D) at baseline and at study completion.	12 weeks
Self-reported measure of Anxiety.	Participants will complete the 40-item State-Trait Anxiety Inventory (STAI) at baseline and at study completion.	12 weeks
Self-reported measure of Sleep Quality.	Participants will complete the Pittsburgh Sleep Quality Index (PSQI) at baseline and at study completion.	12 weeks
Urine screening	Weekly urine screening will be conducted to assess deviations from treatment (use of non prescribed medications or substances).	12 weeks

Collaborators and Investigators

• Sponsor: LiteCure LLC
• Investigators: Principal Investigator: Jerome C Stenehjem, Md, Sharp HealthCare

Study record dates

Study Major Dates

• Study Start (ACTUAL): August 1, 2018
• Primary Completion (ACTUAL): June 1, 2019
• Study Completion (ACTUAL): June 1, 2019

Study Registration Dates

• First Submitted: December 21, 2017
• First Submitted That Met QC Criteria: February 15, 2018
• First Posted (ACTUAL): February 19, 2018

Study Record Updates

• Last Update Posted (ACTUAL): August 26, 2019
• Last Update Submitted That Met QC Criteria: August 21, 2019
• Last Verified: August 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Chronic Pain
• Other Study ID Numbers: PBMT for Chronic Pain

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: There is no intent to share data and no plan formulated at this time.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No